Autolus For Profit
Autolus is in T-cell programming and manufacturing technology.
Investors
Industry:
Regenerative medicine
Estimated Revenue:
$50M to $100M
Last Funding Type:
Series A
Total Funding:
â¬25M
Headquarters:
London, England, United Kingdom
Technology:
Other
Investors Number:
4